V1RB2 Inhibitors
V1RB2 inhibitors belong to a class of chemical agents that specifically target and inhibit the function of a particular protein receptor known as V1RB2. V1RB2 is one of the many receptors in the G protein-coupled receptor (GPCR) superfamily, a vast and diverse group of membrane proteins that play critical roles in cellular signaling. These receptors are characterized by their seven transmembrane domains, which span the cell membrane, and they transduce signals from outside the cell to the inside through conformational changes upon ligand binding. The V1RB2 receptor is encoded by a specific gene and is expressed in various tissues within living organisms. Its natural ligands are typically endogenous substances that, when bound to the receptor, trigger a cascade of intracellular events that result in a specific biological response. The V1RB2 receptor's precise function and the pathways it influences are highly specific and intricately regulated within the body's complex biochemistry.
Inhibitors of V1RB2 have been designed to selectively bind to this receptor and prevent its activation by natural ligands. By doing so, these inhibitors effectively "silence" the receptor's activity, which can have a profound impact on the signaling pathways that the receptor controls. The design of V1RB2 inhibitors requires an in-depth understanding of the receptor's structure and the molecular interactions that occur upon ligand binding. These compounds typically mimic the shape and charge distribution of the natural ligand but differ in such a way that they do not trigger the receptor's usual response. Instead, they occupy the binding site and prevent other molecules from interacting with the receptor. The development of V1RB2 inhibitors is a sophisticated process that involves various fields such as medicinal chemistry, molecular biology, and computational modeling to predict and enhance the affinity and specificity of these molecules to their target receptor. The selectivity of V1RB2 inhibitors is crucial, as it determines their ability to modulate the receptor without affecting other GPCRs, which could lead to unintended consequences due to off-target effects.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Phosphoramidon | 119942-99-3 | sc-201283 sc-201283A | 5 mg 25 mg | $199.00 $632.00 | 8 | |
Phosphoramidon is a metalloprotease inhibitor that can inhibit the activity of neprilysin. Neprilysin degrades enkephalins, which are natural ligands for opioid receptors that can modulate the G-protein-coupled receptor (GPCR) function. Inhibiting neprilysin could indirectly lead to altered opioid receptor activity, potentially affecting V1RB2 signaling indirectly by modulating related GPCR dynamics. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Pertussis toxin is a protein-based inhibitor that specifically targets G-proteins by ADP-ribosylating the alpha subunit, preventing interaction with GPCRs. By inhibiting normal G-protein function, this toxin can indirectly decrease V1RB2 signaling through impaired G-protein coupling and downstream signaling. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
GF 109203X is a potent protein kinase C (PKC) inhibitor. PKC plays a role in phosphorylation of many substrates, including GPCR regulatory proteins. By inhibiting PKC, GF 109203X could indirectly inhibit the phosphorylation state of proteins that modulate V1RB2 activity, thereby decreasing V1RB2 function. | ||||||
Cholesterol | 57-88-5 | sc-202539C sc-202539E sc-202539A sc-202539B sc-202539D sc-202539 | 5 g 5 kg 100 g 250 g 1 kg 25 g | $27.00 $2809.00 $129.00 $210.00 $583.00 $88.00 | 11 | |
Cholesterol is a key component of cell membranes and can influence membrane fluidity and the function of membrane-bound proteins. By modulating the cholesterol level in the membrane, it could indirectly affect V1RB2 signaling by altering receptor localization or function. | ||||||
L-NG-Nitroarginine Methyl Ester (L-NAME) | 51298-62-5 | sc-200333 sc-200333A sc-200333B | 1 g 5 g 25 g | $48.00 $107.00 $328.00 | 45 | |
L-NAME is an inhibitor of nitric oxide synthase (NOS). Nitric oxide (NO) can serve as a diffusible modulator for various cellular processes, including GPCR signaling. By inhibiting NO production, L-NAME could indirectly affect V1RB2 function, as NO can modulate GPCR activity including receptor desensitization and internalization. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a non-selective beta-adrenergic receptor antagonist that can influence adrenergic receptor function and related GPCR signaling. As V1RB2 is a GPCR, the modulation of GPCR pathways by propranolol could indirectly influence V1RB2 functional activity by altering the cellular signaling environment. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). PI3K is involved in various cellular pathways including those affecting GPCR internalization and recycling. By inhibiting PI3K, LY294002 could potentially lead to altered trafficking of V1RB2, indirectly affecting its signaling and receptor availability at the cell surface. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is a selective inhibitor of protein kinase C (PKC). As mentioned earlier, PKC can modulate GPCR function. By inhibiting PKC, chelerythrine could indirectly lead to reduced phosphorylation and thus decreased V1RB2 activity. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A sc-200402B sc-200402C | 50 mg 500 mg 5 g 10 g | $69.00 $364.00 $2500.00 $4100.00 | 11 | |
Clozapine that binds to several dopamine and serotonin receptors, which are GPCRs, and could influence the GPCR signaling network. Although its primary targets are not V1RB2, its broad effects on GPCR signaling can indirectly affect V1RB2 functionQuestion 2: | ||||||